Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics

Bioanalysis

Volumn 4, Issue 20, 2012, Pages 2513-2523

  Lee, Jean W ^a   Salimi Moosavi, Hossein ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; AFLIBERCEPT; ALEMTUZUMAB; ATACICEPT; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; MAPATUMUMAB; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OFATUMUMAB; PALIVIZUMAB; PANITUMUMAB; PERTUZUMAB; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ROMIPLOSTIM; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ANALYTIC METHOD; BINDING AFFINITY; CARDIOTOXICITY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; PHARMACOKINETIC PHARMACODYNAMICS RELEVANCY; PHARMACOLOGICAL PARAMETERS; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN EXPRESSION; RELIABILITY; REVIEW; SIMULATION; THROMBOSIS; VALIDATION PROCESS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; DRUG DISCOVERY; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS;

EID: 84869438561     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.220     Document Type: Review

References (59)

1. Banerjee S, Flores-Rozas H. Monoclonal antibodies for targeted therapy in colorectal cancer. Cancer Biol. Ther. 9(8), 563-571 (2010).
2. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10(5), 301-316 (2010).
3. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41(1), 98-107 (2008).
4. Kharitonenkov A, Shanafelt AB. FGF21: a novel prospect for the treatment of metabolic diseases. Curr. Opin. Investig. Drugs 10(4), 359-364 (2009).
5. Klettner A, Roider J. Treating age-related macular degeneration - interaction of VEGF-antagonists with their target. Mini Rev. Med. Chem. 9(9), 1127-1135 (2009).
6. Lowe PJ. Applying physiological and biochemical concepts to optimize biological drug development. Clin. Pharmacol. Ther. 87(4), 492-496 (2010).
7. Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35(5), 573-591 (2008).
8. Agoram BM. Use of pharmacokinetic/ PD modelling for starting dose selection in first-in-human trials of high-risk biologics. Br. J. Clin. Pharmacol. 67(2), 153-160 (2009).
9. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12(13-14), 540-547 (2007). (Pubitemid 47031663)
10. Lee J, Kelley M, King L et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011).
11. Lee J, Pan Y, O'brian P, Xu R. Development and validation of ligand-binding assays for biomarkers. In:Ligand-Binding Assays: Development, Validation, and Implementation in the Drug Development. Khan M, Findlay J (Eds). John Wiley & Sons, Hoboken, NJ, USA, 129-161 (2010).
12. Tang C, Prueksaritanont T. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target. Pharm. Res. 28(10), 2447-2457 (2011).
13. Betts AM, Clark TH, Yang J et al. The application of target information and preclinical pharmacokinetic/PD modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J. Pharmacol. Exp. Therap. 333(1), 2-13 (2010).
14. Rudge JS, Holash J, Hylton D et al. Inaugural article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl Acad. Sci. USA 104(47), 18363-18370 (2007). (Pubitemid 350210713)
15. Salimi-Moosavi H, Burns D, Miller J et al. A novel approach for the measurement of 'total and free' target proteins in serum samples in the presence of antibody therapeutics. Presented at: American Association of Pharmaceutical Scientists National Biotechnology Conference. Toronto, Canada, 23-24 June 2008.
16. Salimi-Moosavi H, Lee J, Desilva B, Dollgast G. Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. J. Pharm. Biomed. Anal. 51, 1128-1133 (2010).
17. Lu J-F. PK/PD perspective on the measurement of ligand levels across therapeutic areas. Presented at: BioAnalytical Method Development Conference. CA, USA, 6-8 October 2008.
18. Banks R E. Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin. Chem. 54(1), 6-7 (2008). (Pubitemid 351182588)
19. Lee J, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. In:Genomics in Cancer Drug Discovery and Development . Hampton GM, Sikora K (Eds). Elsevier, London, UK, 269-298 (2007). (Pubitemid 44855852)
20. Sinha TK, Khatib-Shahidi S, Yankeelov TE et al. Integrating spatially resolved three-dimensional MALDI IMS with in vivo magnetic resonance imaging. Nat. Methods 5(1), 57-59 (2008).
21. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat. Methods 4(10), 828-833 (2007). (Pubitemid 350055580)
22. Hall M, Lee JW, Spahr C, Lu H, Ortiz R. Ligand binding-mass spectrometry methods for understanding macromolecular drug biotransformation and impact on immunoassay quantification. Presented at: 56th Annual ASMS Conference on Mass Spectrometry and Allied Topics. Denver, CO, USA, 1-5 June 2008.
23. Lee J, Quarmby V, Yang J, Ahene A, Salimi-Moosavi H. Why do we care whether a LBA is measuring 'total' or 'free' protein therapeutic or biomarker? AAPS Ligand Binding Assay Bioanalytical Focus Group Newsletter. July 2008.
24. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatog. B 877(13), 1259-1271 (2009).
25. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3(1), 61-66 (2011).
26. Dong JQ, Salinger DH, Endres CJ et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin. Pharmacokinet. 50(2), 131-142 (2011).
27. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J. Clin. Pharmacol. 49(12), 1382-1402 (2009).
28. Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37(10-11), 1331-1354 (2007). (Pubitemid 350035529)
29. Mager DE, Woo S, Jusko WJ. Scaling PDs from in vitro and preclinical animal studies to humans. Drug Metab. Pharmacokinet. 24(1), 16-24 (2009).
30. Muller PY, Brennan FR. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 85(3), 247-258 (2009).
31. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm. Drug Dispos. 31(4), 253-263 (2010).
32. Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol. Ther. 122(3), 281-301 (2009).
33. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J. Pharmacokinet. Pharmacodyn. 36(4), 341-351 (2009).
34. Lee JW, Ma H. Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins. AAPS J. 9, E164-E170 (2007).
35. Hall MP, Gegg C, Walker K et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J. 12(4), 576-585 (2010).
36. Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J. Pharmacokinet. Pharmacodyn. 37(4), 323-346 (2010).
37. Mould DR, Green B. Pharmacokinetics and PDs of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24(1), 23-39 (2010).
38. Mould DR, Sweeney KR. The pharmacokinetics and PDs of monoclonal antibodies - mechanistic modeling applied to drug development. Curr. Opin. Drug Discov. Develop. 10(1), 84-96 (2007). (Pubitemid 46438261)
39. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and PDs. Clin. Pharmacol. Ther. 84(5), 548-558 (2008).
40. Yeung YA, Wu X, Reyes AE 2nd et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 70(8), 3269-3277 (2010).
41. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725 (2007). (Pubitemid 47327396)
42. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. Amechanism-based binding model for the population pharmacokinetics and PDs of omalizumab. Br. J. Clin. Pharmacol. 63(5), 548-561 (2007). (Pubitemid 46632569)
43. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE PDs and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br. J. Clin. Pharmacol. 68(1), 61-76 (2009).
44. Yang BB, Kido A. Pharmacokinetics and PDs of pegfilgrastim. Clin. Pharmacokinet. 50(5), 295-306 (2011).
45. Cersosimo RJ. Romiplostim in chronic immune thrombocytopenic purpura. Clin. Ther. 31(9), 1887-1907 (2009).
46. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale discovery, for human cytokine profiling. J. Immunol. Methods 340(1), 55-64 (2009).
47. Van Der Graaf PH, Benson N. Systems pharmacology: bridging systems biology and pharmacokinetics-PDs (PKPD) in drug discovery and development. Pharm. Res. 28(7), 1460-1464 (2011).
48. Gleissner B, Schlenk R, Bornhauser M, Berdel WE. Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukaemia - ongoing trials. Onkologie 30(12), 657-662 (2007). (Pubitemid 350247765)
49. Yang BB, Lum P, Chen A et al. Pharmacokinetic and PD perspectives on the clinical drug development of panitumumab. Clin. Pharmacokinet. 49(11), 729-740 (2010).
50. Lennon S, Barton C, Banken L et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J. Clin. Oncol. 27(10), 1685-1693 (2009).
51. Munafo A, Priestley A, Nestorov I, Visich J, Rogge M. Safety, pharmacokinetics and PDs of atacicept in healthy volunteers. Eur. J. Clin. Pharmacol. 63(7), 647-656 (2007). (Pubitemid 46911347)
52. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br. J. Haematol. 150(1), 9-20 (2010).
53. Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and PD model of recombinant human erythropoietin (rHuEPO). J. Pharmacokinet. Pharmacodyn. 34(6), 849-868 (2007). (Pubitemid 350165278)
54. Xu Z, Vu T, Lee H et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J. Clin. Pharmacol. 49(9), 1056-1070 (2009).
55. Mulleman D, Chu Miow Lin D, Ducourau E et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther. Drug Monit. 32(2), 232-236 (2010).
56. Lachmann HJ, Kone-Paut I, Kuemmerle- Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360(23), 2416-2425 (2009).
57. Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206(5), 1029-1036 (2009).
58. Magparangalan DP, Garrett TJ, Drexler DM, Yost RA. Analysis of large peptides by MALDI using a linear quadrupole ion trap with mass range extension. Anal. Chem. 82(3), 930-934 (2010).
59. Wang J, Lee J, Burns D et al. 'Fit-for-purpose' method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J. 11(2), 385-394 (2009).